USING THE HUMAN IMMUNE SYSTEM TO CHANGE THE PARADIGM OF CANCER TREATMENT. CORPORATE OVERVIEW March 2016

Transcription

1 USING THE HUMAN IMMUNE SYSTEM TO CHANGE THE PARADIGM OF CANCER TREATMENT CORPORATE OVERVIEW March 2016

2 Immunome Overview A biotechnology company leveraging tumor immunology to develop cancer therapeutics Experienced management and drug development team Pipeline of antigen-antibody pairs Fully human antibodies engineered for safe and robust anti-tumor activity Uniquely enables ADC and CAR T therapeutic strategies Proprietary platforms RealMab Isolates antibodies from privileged patients (super responders) raised against their own tumors Cancer neo-antigens recognized by these antibodies ScreenMab Patient antibodies screened for desired functional profiles Recent $8.5M Series A Rapidly building out the team and advancing products to the clinic 2

3 Experienced Management Team Jane H. Hollingsworth Executive Chair and Interim CEO Michael J. Morin, PhD President & Chief Scientific Officer Joan Lau, PhD Chief Operating Officer Scott Dessain, MD, PhD Chief Technology Officer & Founder Joel Sussman Chief Financial Officer Shawn D. Bridy VP & Head of Business Development Founder and Former CEO, NuPathe (PATH) sold to TEVA for $300 million Founder and Former EVP, Auxilium (AUXL) sold to ENDP for $2.6 billion Former VP, Secretary & General Counsel of IBAH (IBAH) Former VP Immunology, Antibacterials and Cancer Discovery, Pfizer Former Chief Scientific Officer, Onkaido Therapeutics Advisor to venture-backed and public cancer therapeutics companies Former CEO, Azelon Former CEO, Locus Former R&D Leader and Business Development Executive, Merck Associate Professor, Lankenau Institute for Medical Research Former Instructor, Massachusetts General Hospital Post-doctoral training under Dr. Robert Weinberg, Whitehead Institute Serves as part time CFO of PhaseBio and Galera Therapeutics Former CFO of Adolor, BioRexis, Tetralogic and NuPathe Certified Public Accountant Former Business Development Director, Elan Pharmaceuticals (ELN) Former Executive at GlaxoSmithKline, Global Commercial Strategy, Oncology Former VP of Strategy and Business Development, BTG plc (LSE:BGC)

4 Scientific and Strategic Advisors Brian Daniels, MD Donald Drakeman, PhD Shawn Langer, MD Louis M. Weiner, MD Venture Partner of 5AM Venture Management Senior Advisor, Boston Consulting Group Former SVP of Global Development and Medical Affairs, R&D of Bristol-Myers Squibb Venture Partner, Advent Venture Partners and Fellow of Health Management, University of Cambridge Founder and former CEO, Medarex Founder Genmab BMHS Investments, Operating Partner Former Senior Partner, McKinsey & Company;; leader healthcare private equity practice Professor & Director, Lombardi Cancer Center of Georgetown University, Chair, Dept of Oncology Founder, Jounce Therapeutics Former Chair of Medical Oncology & VP Translational Research at Fox Chase Cancer Center 4

5 Rapid Discovery of Antigen-Antibody Pairs B-cells Sourced from Super-Responders to Checkpoint Inhibitor Therapies Extract Primary B-Cells from Sentinel Lymph Nodes + Create B Cell Fusions Using Proprietary Human Hybridoma Technology (RealMab) = Telomerase and Interleukin-6 Stabilize High-level Human Antibody Expression Generate Stable Human Hybridomas in 22 Days Select Cancer Patients Hybridomas Express Original, Fully Human Antibodies at High Fidelity Initiate Multiplex Functional Screening Process (ScreenMab) Confirm and Adapt to Suitable Format (ADC, CAR T, NK or Bi- Specific) Produce Libraries of Thousands of Antibodies Enriched for Tumor Antigen Binding Results in the Most Meaningful Cancer Specific Antigen Antibody Pairs in 6 Months 5

6 Robust Discovery Stage Pipeline Targeting Novel Antigens Antigens identified suggest diverse MOA Leads suitable for state-of-the-art approaches to targeted therapeutics Antibody Antigen Profile Targeted Indication Suitable Format IMM-002 Known cancer target involved in cell invasion Cancer cells (vs normal) express the antigen on the outer plasma membrane Breast, Lung T Cell Engager IMM-003 Internalizing Breast, Lung ADC IMM-005 IMM-009 Expression in tumor (versus normal) human tissue Post translational modification Activity in triple negative BRCA cell lines Internalizing Breast, Colon Breast, Lung T Cell Engager IMM-010 Internalizing Breast, Lung ADC ADC IMM-045 IgM post germinal center CDC activity Major Solid Tumors T Cell Engager 6

7 IMM-002: The First Recognition of this Antigen Present on the Outer Plasma Membrane A known cancer target involved in cell invasion Its location on the outer cell membrane was previously unknown Antigen confirmed via mutational analyses In normal cells, it is only intracellular Extracellular expression is induced by the genetic changes converting a normal human cell into a cancer cell The IMM-002 antigen does not internalize Antibody Antigen Profile (Features) Expression Targeted Indication Suitable Format IMM-002 Cancer (vs normal) cell express the antigen on the outer plasma membrane Known cancer target involved in cell invasion Antigen is in every cell, but overexpressed in many tumor types Breast, lung ADCC, CAR T 7

8 IMM-002 Antigen Is Expressed on Diverse Tumor Types Antibody IMM-002 Antigen Profile (Features) Cancer (vs normal) cell express the antigen on the outer plasma membrane Known cancer target involved in cell invasion Expression Antigen is in every cell, but overexpressed in many tumor types Targeted Indication Suitable Format Breast, lung ADCC, CAR T A549 Lung cancer MDA MB 231 claudin low breast cancer IMM-002 antigen expressed by all three breast cancer types as well as lung adenocarcinoma MCF7 Breast luminal A (ER+PR+) SK-BR-3 Breast HER2 8

9 IMM-002 Antigen Mutants Fail to Reach the Outer Plasma Membrane Antigen present in cells Outer plasma membrane expression only in cancer cells Loss of function mutation prevents translocation to the outer plasma membrane 9

10 Multiple Antibody Leads Internalize, Suggesting Potential as ADCs Isotype control 2 AB only Red signals denote endosomes that have internalized the mabs. Nuclei are stained blue. Extracellular signals are artifacts of cell fixation. 10

11 Antigen-Antibody Identification Companies Human Immune Response Informed Target Discovery Computational Repertoire Screening Function Based Repertoire Screening Non-Human Target Discovery 11

12 Novel Antigen-Antibody Companies and Leads Are in High Demand Recent Antigen-Antibody Deals Juno Therapeutics Adds Next-Generation Single Cell Sequencing Capabilities Through Acquisition of AbVitro Jan 2016 Atreca, Inc., Completes Oversubscribed $56 Million Series A Funding to Advance Pipeline of Novel Cancer Nov 2015 MD Anderson Cancer Center and Theraclone Launch New Immuno-Oncology Company OncoResponse with $10 Million Series A Oct 2015 bluebird bio and Five Prime Therapeutics Enter into License Agreement for Novel Antibodies to Develop Chimeric Antigen Receptor T Cell Therapy May 2015 $130M Acquisition $56M Series A $9.5M Series A $130M Potential per Product AbVitro s technology allows for the identification of fully-human, natively paired binders directly from cancer patients. This capability enables the generation of binders that recognize known targets as well as the discovery of novel cancer antigen targets to provide a better understanding of the natural immune response to cancer...payment of Approximately $78 M and 1,289,193 Shares of Stock. Atreca, Inc., a company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today the completion of its Series A funding with a total investment of $56 million A patient s own anti-cancer immune response is the key phenomenon driving the exciting clinical outcomes seen with checkpoint inhibitors and other immune activators. OncoResponse closed a Series A financing round worth $9.5 million the startup will utilize Theraclone s I-STAR platform this technology screens antibodies produced by the human body in order to identify those that have particular sensitivity and reactivity that might be useful for cancer drugs. Five Prime will provide bluebird bio exclusive rights to its novel human antibodies to the target upfront payment and subsequent milestone payments to Five Prime, which together could total over $130 million per licensed product if certain development, regulatory, and commercial milestones are achieved. 12

13 Expanding Patent Portfolio Invention Claim(s) Status Fusion partner cell lines and uses thereof A novel fusion partner cell line for the creation of hybrid cells expressing human antibodies Method of making hybrid cells that express useful antibodies IMM-002 Antigen binding molecules and uses thereof Anti-IMM-005 Antigen and uses thereof A fusion partner cell with htert and mil-6 US Patent 7,491,530 Issued 2009 Improved fusion partner US Patent 8,557,575 Issued 2013 Selection and pretreatment of B cells Composition of a molecule binding to cancer specific expression of TARGET1 mab and antibody fragments binding to TARGET2 US Patent 8,999,707 Issued 2015 Issued in Europe Pending in Japan US Application 14/961,492 PCT/US2015/ Patent Application Filed Patent applications are being filed on novel antigen-antibody pairs as they are discovered and validated 13

14 Immunome Overview A biotechnology company leveraging tumor immunology to develop cancer therapeutics Experienced management and drug development team Pipeline of antigen-antibody pairs Fully human antibodies engineered for safe and robust anti-tumor activity Uniquely enables ADC and CAR T therapeutic strategies Proprietary platforms RealMab Isolates antibodies from privileged patients (super responders) raised against their own tumors. Cancer neo-antigens recognized by these antibodies ScreenMab Patient antibodies screened for desired functional profiles Recent $8.5M Series A Rapidly building out the team and advancing products to the clinic 14

15 Contact Us Investors Jane H. Hollingsworth, Executive Chair & Interim CEO Partnering & Collaboration Shawn D. Bridy, VP & Head of Business Development Immunome, Inc. 15